• Erythromycin A, EvoPure packaged and labeled.

click on thumbnail to zoom
SKU: E027

Size  
Quantity:
  Click 'Bulk Order' for 10 or more
Price: make selection(s)
Description

Erythromycin A, EvoPure® is a highly purified form of the macrolide antibiotic Erythromycin A and is a natural product.  Erythromycin is composed of Erythromycin A, B, C, D, and additional impurities.  Erythromycin A is the most active component. 

For other Erythromycin products, click here.

    CAS Number

    59319-72-1

    Molecular Formula

    C37H67NO13 · 2H2O

    Molecular Weight

    769.96

    Mechanism of Action

    Macrolide antibiotics inhibit bacterial growth by targeting the 50S ribosomal subunit of the 70S ribosome preventing aminoacyl translocation of the A-site to P-side and peptide bond formation during protein synthesis. Resistance to Erythromycin is commonly attributed to mutations in 50S rRNA preventing erythromycin binding allowing the cell to synthesize proteins free of error. In acidic aqueous media, Erythromycin A is degraded via intramolecular dehydration to form erythromycin-6,9-hemiketal and then anhydroerythromycin, both of which possess little antimicrobial activity. (Fiese and Staffen, 1990).

    Storage Conditions

    -20°C

    Tariff Code

    2941.50.0000

    Spectrum

    Effective against Gram-positive and Gram-negative bacteria.

Applications

    Application

    Erythromycin A, EvoPure® can be used as a reference standard or to study the individual properties of Erythromycin A. Reference standards are well characterized, highly pure compounds that can be used to help identify and/or quantify impurities in pharmaceutical compounds and antimicrobials.

    Eukaryotic Cell Culture Applications

    The production of bioactive compounds in heterologous hosts has become a valuable tool for the investigation of biosynthetic pathways. The reconstruction of the Erythromycin A biosynthetic pathway was done in E. coli (Zhang et al, 2010).  The biosynthesis of 6-deoxyerythronolide B (6-dEB), the macrocyclic core of Erythromycin A, in an engineered strain of E. coli was described (Pfeifer et al., 2001).


Specifications

    Form

    Powder

    Source

    Saccharopolyspora erythraea

References

    References

    Fiese EF and Staffen SH (1990) Comparison of the acid stability of azithromycin and erythromycin A. J. Antimicrob. Chemother. 25(A):39-47

    Kibwage IO et al (1985) Antibacterial activities of Erythromycins A, B, C, and D and some of their derivatives. Antimicrob. Agents Chemother. 28(5):630-33

    Weber T et al (2010) Making E. coli an erythromycin production plant. Chem. & Biol. 17(11):1168-1169

    Zhang H et al (2010) Complete biosynthesis of erythromycin A and designed analogs using E. coli as a heterologous host. Chem. & Biol. 17(11):1232-1240

Other Items In This Category